|
241 |
Rituximab plus leflunomide in rheumatoid arthritis: a randomized, placebo-controlled, investigator-initiated clinical trial (AMARA study)
Behrens, Frank. - Würzburg : Universität Würzburg, 2024
|
|
|
|
242 |
Safety, tolerability, and efficacy of fasudil in amyotrophic lateral sclerosis (ROCK-ALS)
Koch, Jan Christoph. - Ludwig-Maximilians-Universität München, 2024
|
|
|
|
243 |
Silexan does not affect driving performance after single and multiple dose applications: Results from a double-blind, placebo and reference-controlled study in healthy volunteers
Möller, Hans-Jürgen. - Würzburg : Universität Würzburg, 2024
|
|
|
|
244 |
The oral intake of specific Bioactive Collagen Peptides (BCP) improves gait and quality of life in canine osteoarthritis patients—A translational large animal model for a nutritional therapy option
Dobenecker, Britta. - Ludwig-Maximilians-Universität München, 2024
|
|
|
|
245 |
Topical Treatment Is Effective and Safe for Acute Ankle Sprains
Gerdesmeyer, Ludger. - Jena : Friedrich-Schiller-Universität Jena, 2024
|
|
|
|
246 |
Triheptanoin Did Not Show Benefit versus Placebo for the Treatment of Paroxysmal Movement Disorders in Glut1 Deficiency Syndrome: Results of a Randomized Phase 3 Study
De Giorgis, Valentina. - Aachen : Universitätsbibliothek der RWTH Aachen, 2024
|
|
|
247 |
Patient-Reported Satisfaction with Hair Regrowth in a Study of Ritlecitinib in Alopecia Areata: Results from ALLEGRO-2b/3
Enthalten in Dermatology Bd. 240, 2024, Nr. 5-6: 767-777. 11 S.
|
|
|
|
248 |
Efficacy and Safety of Secukinumab for the Treatment of Psoriasis: A Meta-Analysis of Pivotal Phase III Trials
Enthalten in Dermatology Bd. 240, 2024, Nr. 2: 271-281. 11 S.
|
|
|
|
249 |
Abrocitinib Provides Rapid and Sustained Improvement in Skin Pain and Is Associated with Improved Quality of Life Outcomes in Adult and Adolescent Patients with Moderate-to-Severe Atopic Dermatitis
Enthalten in Dermatology Bd. 240, 2024, Nr. 2: 243-253. 11 S.
|
|
|
|
250 |
A Randomized, Double-Blind, Placebo-Controlled, Multicenter, 16-Week Trial to Evaluate the Efficacy and Safety of FB-401 in Children, Adolescents, and Adult Subjects (Ages 2 Years and Older) with Mild-to-Moderate Atopic Dermatitis
Enthalten in Dermatology Bd. 240, 2024, Nr. 1: 85-94. 10 S.
|
|
Administration
